logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Sphingosine 1-phosphate Receptor Modulator class drugs

    FiltersReset Filters
    10 results

    • fingolimod

      (FINGOLIMOD)
      Aurobindo Pharma Limited
      Usage: Fingolimod capsules are indicated for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 and older, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • fingolimod

      (Fingolimod)
      Camber Pharmaceuticals, Inc.
      Usage: Fingolimod capsules are indicated for treating relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients aged 10 years and older.

    • fingolimod

      (Fingolimod)
      Dr. Reddy's Laboratories Inc
      Usage: Fingolimod capsules are indicated for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 and older, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • fingolimod

      (FINGOLIMOD)
      Biocon Pharma Inc.
      Usage: Fingolimod capsules are indicated for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 years and older, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • fingolimod

      (FINGOLIMOD)
      Quallent Pharmaceuticals Health LLC
      Usage: Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients aged 10 and older.

    • mayzent

      (siponimod)
      Novartis Pharmaceuticals Corporation
      Usage: MAYZENT is indicated for treating relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • ponvory

      (Ponesimod)
      Janssen Pharmaceuticals, Inc.
      Usage: PONVORY is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • ponvory

      (Ponesimod)
      Vanda Pharmaceuticals Inc.
      Usage: PONVORY is indicated for treating relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • tascenso odt

      (Fingolimod Lauryl Sulfate)
      Cycle Pharmaceuticals Ltd
      Usage: TASCENSO ODT is indicated for treating relapsing forms of multiple sclerosis (MS) in patients aged 10 and older, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

    • zeposia

      (ozanimod hydrochloride)
      Celgene Corporation
      Usage: ZEPOSIA is indicated for the treatment of relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease) and moderately to severely active ulcerative colitis in adults.